February 18, 2022
Recipharm acquires Vibalogics and Arranta Bio
Recipharm, a global contract development and manufacturing organisation (CDMO), has announced the acquisition of Vibalogics, a virotherapy CDMO and a…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
February 18, 2022
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
Sandoz has announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest…
February 17, 2022
FDA accepts for priority review BMS’s Breyanzi as a second-line therapy for relapsed or refractory large B-cell lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics…
February 17, 2022
Intellia and ONK Therapeutics announce collaboration to advance allogeneic CRISPR-edited NK cell therapies for the treatment of patients with cancer
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd.,…
February 17, 2022
miDiagnostics ultra-fast COVID-19 PCR test succeeds in Brussels airport pilot study
miDiagnostics, a POC diagnostics company backed by Belgian Family Offices, announces the success of the Brussels Airport pilot study for…
February 16, 2022
Novel Concepts Medical announces breakthrough in COVID-19 research
The startup company Novel Concepts Medical has announced that its novel plant-based treatment has resulted in successfully inhibiting the COVID-19…
February 16, 2022
German Federal Court of Justice upholds AOP’s license rights in Ropeginterferon and PEC’s liability for damages
AOP Orphan Pharmaceuticals announced that on Monday February 14, 2022 the German Federal Court of Justice decided on PEC’s challenge…
February 16, 2022
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate…
February 16, 2022
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation
TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
February 15, 2022
Topas Therapeutics Appoints Cristina de Min as Chief Medical Officer
Topas Therapeutics GmbH (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of…